| (210) | Number of the EPO application | 16771043 |
| (220) | Filing date of the EPO application | 2016.09.13 |
| (80) | EPO patent specification publication (B) | EPB nr. 16/2021, 2021.04.21 |
| (110) | EPO patent number | 3349740 |
| (21) | Number of the application | e 2018 0711 |
| (71) | Name(s) of applicant(s), code of the country | JANSSEN PHARMACEUTICA NV, BE; |
| (72) | Name(s) of inventor(s), code of the country | ROSENTHAL Norman R., US;
ROTHENBERG Paul, US;
POLIDORI David C., US;
WAYS Douglas K., US;
STEIN Peter P., US; |
| (73) | Name(s) of owner(s), code of the country | JANSSEN PHARMACEUTICA NV, BE; |
| (54) | Title of the invention | CO-THERAPY COMPRISING CANAGLIFLOZIN AND PHENTERMINE FOR USE IN THE TREATMENT OF OBESITY AND OBESITY RELATED DISORDERS |
| (13) | Kind-of-document code | A1 |
| (51) | International Patent Classification | A61K 31/137 (2006.01.01); A61K 31/7042 (2006.01.01); A61P 3/04 (2006.01.01); A61P 3/00 (2006.01.01); A61P 9/00 (2006.01.01); A61P 9/12 (2006.01.01); A61P 13/00 (2006.01.01); A61P 1/16 (2006.01.01); A61P 43/00 (2006.01.01) |
| (19) | Country | BE |
| (41) | Date of publication of the application | 2018.08.31 |
| (30) | Priority | 201562218842 P, 2015.09.15, US; 201662306110 P, 2016.03.10, US; 201615262038, 2016.09.12, US |
| (86) | International application | PCT/US2016/051435, 2016.09.13 |
| (87) | International publication | WO 2017/048670, 2017.03.23 |